PT1666496E - Composto de interferão β - Google Patents

Composto de interferão β Download PDF

Info

Publication number
PT1666496E
PT1666496E PT47724083T PT04772408T PT1666496E PT 1666496 E PT1666496 E PT 1666496E PT 47724083 T PT47724083 T PT 47724083T PT 04772408 T PT04772408 T PT 04772408T PT 1666496 E PT1666496 E PT 1666496E
Authority
PT
Portugal
Prior art keywords
interferon
beta composite
beta
composite
Prior art date
Application number
PT47724083T
Other languages
English (en)
Inventor
Tadatsugu Taniguchi
Hideki Narumi
Yoshiaki Tsushima
Koji Yamashita
Saburou Sone
Miyuki Sato
Original Assignee
Toray Industries
Tadatsugu Taniguchi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries, Tadatsugu Taniguchi filed Critical Toray Industries
Publication of PT1666496E publication Critical patent/PT1666496E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/565IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PT47724083T 2003-08-25 2004-08-24 Composto de interferão β PT1666496E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003299850 2003-08-25

Publications (1)

Publication Number Publication Date
PT1666496E true PT1666496E (pt) 2014-06-24

Family

ID=34213782

Family Applications (1)

Application Number Title Priority Date Filing Date
PT47724083T PT1666496E (pt) 2003-08-25 2004-08-24 Composto de interferão β

Country Status (11)

Country Link
US (2) US7691975B2 (pt)
EP (1) EP1666496B1 (pt)
JP (1) JP4850514B2 (pt)
KR (1) KR101157679B1 (pt)
CN (2) CN101880326B (pt)
AU (1) AU2004266969B2 (pt)
CA (1) CA2536643C (pt)
ES (1) ES2452640T3 (pt)
PL (1) PL1666496T3 (pt)
PT (1) PT1666496E (pt)
WO (1) WO2005019260A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101163716B (zh) * 2005-04-30 2011-09-07 成都生物制品研究所 白细胞介素-6聚乙二醇结合物及其制备方法和应用
JP5563475B2 (ja) * 2007-12-20 2014-07-30 メルク セローノ ソシエテ アノニム Pegインターフェロン−ベータ製剤
GB0912485D0 (en) * 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method
CA2850469C (en) 2011-10-01 2020-07-07 Glytech, Inc. Glycosylated polypeptide and pharmaceutical composition containing same
EP2821079A4 (en) * 2012-02-29 2016-05-04 Toray Industries MEANS FOR SUPPRESSING BODY CAVITIES
BR112015024423B1 (pt) 2013-03-29 2023-04-25 Glytech, Inc Polipeptídeo glicosilado tendo atividade de interferon ?, composição farmacêutica e uso de um polipeptídeo glicosilado
JP2017100946A (ja) * 2014-03-28 2017-06-08 東レ株式会社 悪液質の治療剤又は予防剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985003934A1 (en) 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
EP0229108B1 (en) * 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DK1037658T3 (da) * 1997-12-19 2002-09-30 Applied Research Systems IFNAR2/IFN-kompleks
EP2599503B1 (en) * 1998-10-16 2017-05-17 Biogen MA Inc. Polymer conjugates of interferon beta-1A and uses thereof
CA2382066C (en) * 1999-08-20 2006-11-21 Honeybaked Ham, Inc. Apparatus for coating meat
BR0013638A (pt) 1999-08-27 2002-05-14 Maxygen Aps Novas moléculas semelhantes a interferon beta
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
JP4593048B2 (ja) * 1999-12-24 2010-12-08 協和発酵キリン株式会社 分岐型ポリアルキレングリコール類
US7226903B2 (en) * 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
JP2004035515A (ja) 2002-07-05 2004-02-05 Toray Ind Inc インターフェロンβ複合体の製造方法

Also Published As

Publication number Publication date
CN101880326A (zh) 2010-11-10
CA2536643A1 (en) 2005-03-03
US7691975B2 (en) 2010-04-06
US7915386B2 (en) 2011-03-29
AU2004266969A1 (en) 2005-03-03
KR101157679B1 (ko) 2012-06-20
ES2452640T3 (es) 2014-04-02
CA2536643C (en) 2013-11-12
EP1666496A4 (en) 2006-09-13
WO2005019260A1 (ja) 2005-03-03
EP1666496A1 (en) 2006-06-07
CN101880326B (zh) 2018-02-16
EP1666496B1 (en) 2014-03-12
CN1871257A (zh) 2006-11-29
JP4850514B2 (ja) 2012-01-11
CN100519581C (zh) 2009-07-29
KR20060134905A (ko) 2006-12-28
US20100145017A1 (en) 2010-06-10
PL1666496T3 (pl) 2014-08-29
JPWO2005019260A1 (ja) 2007-11-01
AU2004266969B2 (en) 2010-02-25
US20060246034A1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
HUP0600113A2 (en) Composite wallpanel
GB2409458B (en) Composite materials
GB2386836B (en) Anti-cancer combinations
HK1095806A1 (en) Organic-inorganic composite
GB0322140D0 (en) Combinations
HK1081463A1 (en) Antineplastic combinations
PL371113A1 (en) Composite section member
EP1627731A4 (en) LAMINATE
HU0900090V0 (en) Brick composite
EP1698458A4 (en) THE MINE
GB0307975D0 (en) Composite structure
GB0321699D0 (en) Fibre-plastics composite
PT1666496E (pt) Composto de interferão β
GB0220510D0 (en) Composite board
GB2421742B (en) Structural arrangement
GB0510737D0 (en) Rigid composite structure
EP1701926A4 (en) ORGANIC-INORGANIC COMPOSITE
GB0208304D0 (en) Composite structures
GB0315042D0 (en) Composite material
GB0306072D0 (en) Laminate
GB0318333D0 (en) Laminate
GB0313210D0 (en) Composite structure
AU2003267595A8 (en) Improved composite structures
GB0401752D0 (en) Cabin
GB0321391D0 (en) Flexi-facial plus